ArriVent BioPharma, Inc. Common Stock (AVBP) — Long-term Investment Intensity
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Long-term Investment Intensity of 1.6% as of September 2025. Long-term investments of $5.11 Million represent 1.6% of total assets of $326.56 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check ArriVent BioPharma, Inc. Common Stock (AVBP) asset resilience to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
ArriVent BioPharma, Inc. Common Stock Long-term Investment Intensity (2024–2024)
This chart shows how ArriVent BioPharma, Inc. Common Stock's Long-term Investment Intensity has evolved across 1 annual periods from 2024 to 2024. As of September 2025, the intensity stands at 1.6%, reflecting long-term investments of $5.11 Million against total assets of $326.56 Million USD. For the complete balance sheet picture, see AVBP current and non-current assets.
Annual Long-term Investment Intensity for ArriVent BioPharma, Inc. Common Stock (2024–2024)
The table below presents the year-by-year Long-term Investment Intensity for ArriVent BioPharma, Inc. Common Stock from 2024 to 2024, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read ArriVent BioPharma, Inc. Common Stock (AVBP) financial obligations for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 17.3% | $47.68 Million | $274.94 Million | — |